GLP-1 patches represent an emerging transdermal delivery system designed to administer glucagon-like peptide-1 receptor agonists through the skin, potentially offering an alternative to traditional injections for type 2 diabetes and weight management
These transformations are significantly better in users who follow structured exercise protocols
Contact your provider promptly if you experience severe or persistent gastrointestinal symptoms while using both medications, including: severe diarrhea lasting more than 24 hours, signs of dehydration (decreased urination, dizziness, extreme thirst, dry mouth), persistent vomiting preventing adequate fluid intake, severe abdominal pain or cramping, or blood in stool
Wegovy helps reduce appetite and increase feelings of fullness, which may lead to reduced food intake
About one in four (27%) GLP-1 users report having health insurance but say they paid the full cost themselves